BRPI0819210A2 - Anticorpos de proteína g anti-rsv - Google Patents

Anticorpos de proteína g anti-rsv

Info

Publication number: BRPI0819210A2
Authority: BR; Brazil
Prior art keywords: rsv; protein antibodies; antibodies; protein
Prior art date: 2007-10-25

Application number

BRPI0819210-3A

Other languages

English (en)

Inventor

Lawrence M Kauvar

Ellen J Collarini

Bruce Keyt

Orit Foord

Original Assignee

Trellis Bioscience Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-10-25

Filing date

2008-10-24

Publication date

2015-06-23

2008-10-24 Application filed by Trellis Bioscience Inc filed Critical Trellis Bioscience Inc

2015-06-23 Publication of BRPI0819210A2 publication Critical patent/BRPI0819210A2/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Breeding Of Plants And Reproduction By Means Of Culturing (AREA)

BRPI0819210-3A 2007-10-25 2008-10-24 Anticorpos de proteína g anti-rsv BRPI0819210A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US46907P	2007-10-25	2007-10-25
US8940108P	2008-08-15	2008-08-15
PCT/US2008/081175 WO2009055711A2 (en)	2007-10-25	2008-10-24	Anti-rsv g protein antibodies

Publications (1)

Publication Number	Publication Date
BRPI0819210A2 true BRPI0819210A2 (pt)	2015-06-23

Family

ID=40580419

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0819210-3A BRPI0819210A2 (pt)	2007-10-25	2008-10-24	Anticorpos de proteína g anti-rsv

Country Status (14)

Country	Link
US (3)	US7736648B2 (pt)
EP (1)	EP2214711B1 (pt)
JP (2)	JP5808536B2 (pt)
KR (1)	KR101671452B1 (pt)
CN (1)	CN101808663B (pt)
AU (1)	AU2008316703B2 (pt)
BR (1)	BRPI0819210A2 (pt)
CA (1)	CA2703667C (pt)
IL (1)	IL205257A (pt)
MX (1)	MX2010004482A (pt)
NZ (1)	NZ585589A (pt)
RU (1)	RU2526517C2 (pt)
WO (1)	WO2009055711A2 (pt)
ZA (1)	ZA201003131B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2003298738A1 (en) *	2002-11-26	2004-06-18	Su-Ming Chiang	Liposomal formulations
BRPI0819210A2 (pt) *	2007-10-25	2015-06-23	Trellis Bioscience Inc	Anticorpos de proteína g anti-rsv
EP2780366A2 (en)	2011-11-17	2014-09-24	AIMM Therapeutics B.V.	Rsv g protein specific antibodies
HUE037186T2 (hu) *	2011-12-28	2018-08-28	Immunoqure Ag	Eljárás humán antitestek izolálására
US10131709B2 (en)	2011-12-28	2018-11-20	Immunoqure Ag	Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
WO2013119419A1 (en)	2012-02-08	2013-08-15	North Carolina State University	Treatment of allergic diseases with recombinant antibodies
TWI659968B (zh)	2013-03-14	2019-05-21	再生元醫藥公司	針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
AU2014255864B2 (en) *	2013-04-15	2019-07-18	Janssen Vaccines & Prevention B.V.	Human antibodies binding to RSV G protein
CN111303278B (zh) *	2013-04-15	2022-09-06	扬森疫苗与预防公司	结合到rsv g蛋白的人类抗体
WO2014170258A1 (en) *	2013-04-15	2014-10-23	Crucell Holland B.V.	Human antibodies binding to rsv g proteins
WO2015120474A1 (en) *	2014-02-10	2015-08-13	Igm Biosciences, Inc.	Iga multi-specific binding molecules
CN103911389A (zh) *	2014-04-09	2014-07-09	南昌大学	一种检测人呼吸道合胞病毒抗体的g和f蛋白的制备方法
DK3227339T3 (da)	2014-12-05	2022-01-10	Memorial Sloan Kettering Cancer Center	Kimæriske antigenreceptorer rettet mod g-protein-koblet receptor og anvendelser deraf
AU2015357535B2 (en)	2014-12-05	2020-05-14	Eureka Therapeutics, Inc.	Antibodies targeting G-protein coupled receptor and methods of use
CN106496324B (zh)	2015-11-30	2020-01-14	天津昊免生物技术有限公司	一种抗呼吸道合胞病毒的全人源抗体
CN105542003B (zh) *	2016-03-01	2019-12-06	苏州博泰神州生物技术有限公司	一种针对rsv粘附g蛋白表面抗原的全人源单克隆抗体
JP7127859B2 (ja)	2016-11-09	2022-08-30	ノースカロライナステートユニバーシティ	キメラタンパク質を用いたアレルギー疾患の治療
JP7005638B2 (ja)	2017-01-27	2022-02-04	エヌジーエムバイオファーマシューティカルス，インコーポレーテッド	グルカゴン受容体結合タンパク質及びその使用方法
EP3694548A4 (en) *	2017-10-13	2021-10-20	Trellis Bioscience, LLC	CONFORMATIONAL EPITOPES IN THE CENTRAL PRESERVED REGION OF THE G PROTEIN OF RESPIRATORY SYNCYTIAL VIRUS
WO2019183437A1 (en)	2018-03-23	2019-09-26	North Carolina State University	Methods and compositions for antibody to high affinity receptor for ige
EP3829636A1 (en)	2018-07-27	2021-06-09	NGM Biopharmaceuticals, Inc.	Use of glucagon receptor antagonists with immunotherapeutic agent
WO2020033742A1 (en) *	2018-08-08	2020-02-13	Trellis Bioscience, Llc	Improved rsv passive and active vaccines
WO2020175660A1 (ja)	2019-02-28	2020-09-03	Ｋｍバイオロジクス株式会社	Ｒｓｖｆ／ｇキメラワクチン
EP4025513A4 (en)	2019-09-06	2023-10-04	Silgan White Cap LLC	HINGED CLOSURE MEANS WITH A CLIP
WO2021053240A1 (en) *	2019-09-20	2021-03-25	Universiteit Antwerpen	A novel human respiratory syncytial virus strain and its use
WO2021113780A1 (en)	2019-12-06	2021-06-10	Juno Therapeutics, Inc.	Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
WO2023081880A1 (en)	2021-11-08	2023-05-11	Silgan White Cap LLC	Protrusion on container neck
JP2025527263A (ja) *	2022-08-02	2025-08-20	ノナ・バイオサイエンシズ（スーチョウ）カンパニー，リミテッド	Ｍｓｌｎ抗体－薬物コンジュゲート
WO2025106427A1 (en) *	2023-11-14	2025-05-22	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv)
WO2025194126A1 (en) *	2024-03-15	2025-09-18	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Respiratory syncytial virus (rsv) g and f antibodies with high rsv-neutralizing potency

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2160119C2 (ru) *	1993-05-25	2000-12-10	Американ Цианамид Компани	Вакцинная композиция, содержащая белок респираторно-синцитиального вируса (варианты)
US6020182A (en) *	1996-07-12	2000-02-01	Connaught Laboratories Limited	Subunit respiratory syncytial virus vaccine preparation
FR2766192B1 (fr) *	1997-07-17	2001-07-13	Pf Medicament	Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
US6642062B2 (en)	1998-09-03	2003-11-04	Trellis Bioinformatics, Inc.	Multihued labels
US7083950B2 (en)	1998-09-25	2006-08-01	Regeneron Pharmaceuticals, Inc.	High affinity fusion proteins and therapeutic and diagnostic methods for use
WO2000043040A1 (en)	1999-01-22	2000-07-27	The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services	Methods for the prevention and treatment of diseases caused by an inflammatory response mediated by endogenous substance p by using anti-substance p antibodies
EP1334119B2 (en) *	2000-10-18	2018-11-28	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Compositions and methods for modulating rsv infection and immunity
US7413868B2 (en)	2003-11-05	2008-08-19	Trellis Bioscience, Inc.	Use of particulate labels in bioanalyte detection methods
JP4736037B2 (ja) *	2005-10-26	2011-07-27	株式会社イーベック	ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
CN1986569A (zh) *	2005-12-23	2007-06-27	首都儿科研究所	人源抗呼吸道合胞病毒中和性基因工程Fab抗体
JPWO2007094423A1 (ja)	2006-02-15	2009-07-09	株式会社イーベック	ヒトサイトメガロウイルスに結合するヒトのモノクローナル抗体並びにその抗原結合部分
US20100040606A1 (en) *	2006-03-06	2010-02-18	Symphogen A/S	Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
EP2041570A4 (en)	2006-07-12	2010-02-24	Trellis Bioscience Inc	CellSpotTM APPLICATIONS
BRPI0819210A2 (pt) *	2007-10-25	2015-06-23	Trellis Bioscience Inc	Anticorpos de proteína g anti-rsv

2008
- 2008-10-24 BR BRPI0819210-3A patent/BRPI0819210A2/pt not_active IP Right Cessation
- 2008-10-24 CA CA2703667A patent/CA2703667C/en active Active
- 2008-10-24 MX MX2010004482A patent/MX2010004482A/es active IP Right Grant
- 2008-10-24 CN CN200880117420.0A patent/CN101808663B/zh not_active Expired - Fee Related
- 2008-10-24 NZ NZ585589A patent/NZ585589A/en not_active IP Right Cessation
- 2008-10-24 US US12/258,260 patent/US7736648B2/en active Active
- 2008-10-24 WO PCT/US2008/081175 patent/WO2009055711A2/en not_active Ceased
- 2008-10-24 AU AU2008316703A patent/AU2008316703B2/en not_active Ceased
- 2008-10-24 EP EP08841063.4A patent/EP2214711B1/en active Active
- 2008-10-24 JP JP2010531283A patent/JP5808536B2/ja active Active
- 2008-10-24 KR KR1020107011433A patent/KR101671452B1/ko not_active Expired - Fee Related
- 2008-10-24 RU RU2010120879/10A patent/RU2526517C2/ru not_active IP Right Cessation
2010
- 2010-04-22 IL IL205257A patent/IL205257A/en not_active IP Right Cessation
- 2010-05-04 ZA ZA2010/03131A patent/ZA201003131B/en unknown
- 2010-05-12 US US12/778,933 patent/US8273354B2/en active Active
2012
- 2012-09-25 US US13/626,852 patent/US9321830B2/en active Active
2015
- 2015-01-16 JP JP2015006644A patent/JP2015078231A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
CA2703667A1 (en)	2009-04-30
AU2008316703A1 (en)	2009-04-30
JP5808536B2 (ja)	2015-11-10
IL205257A0 (en)	2010-12-30
AU2008316703B2 (en)	2012-09-27
NZ585589A (en)	2012-07-27
EP2214711A2 (en)	2010-08-11
KR20100091195A (ko)	2010-08-18
WO2009055711A2 (en)	2009-04-30
KR101671452B1 (ko)	2016-11-17
AU2008316703A2 (en)	2010-07-22
ZA201003131B (en)	2011-03-30
EP2214711A4 (en)	2011-12-21
RU2010120879A (ru)	2011-11-27
MX2010004482A (es)	2010-07-06
US20130034564A1 (en)	2013-02-07
US8273354B2 (en)	2012-09-25
US9321830B2 (en)	2016-04-26
CN101808663A (zh)	2010-08-18
CN101808663B (zh)	2015-09-30
IL205257A (en)	2014-12-31
US20090130120A1 (en)	2009-05-21
JP2015078231A (ja)	2015-04-23
US7736648B2 (en)	2010-06-15
WO2009055711A3 (en)	2009-09-24
EP2214711B1 (en)	2018-08-15
JP2011500091A (ja)	2011-01-06
CA2703667C (en)	2015-12-29
RU2526517C2 (ru)	2014-08-20
US20100285022A1 (en)	2010-11-11

Legal Events

Date	Code	Title	Description
2015-10-27	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 3A ANUIDADE
2016-01-26	B08G	Application fees: restoration [chapter 8.7 patent gazette]
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-03-27	B15K	Others concerning applications: alteration of classification	Ipc: C07K 16/10 (2006.01), A61K 39/00 (2006.01)
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-08-21	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2018-12-11	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2485 DE 21-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
CY2019004I2 (el)	2019-11-27	Τροποποιημενα αντισωματα αντι-ιl-23ρ19
EP2214711A4 (en)	2011-12-21	ANTI-RSV G PROTEIN ANTIBODY
BRPI0918947A2 (pt)	2015-12-01	proteína de fusão de anticorpo
IL287311A (en)	2021-12-01	Antibodies and processes for preparing the same
DK2066695T3 (da)	2013-06-10	Anti-myostatin-antistoffer
DK2131860T3 (da)	2014-01-13	Anti-sclerostin-antistoffer
PT2195026E (pt)	2014-03-31	Anticorpos anti-esclerostina
BRPI0819165A2 (pt)	2015-06-23	Anticorpos anti-vegf
BRPI0820073A2 (pt)	2015-06-23	Anticorpos anti-axl
IL212175B (en)	2019-08-29	Muc1* antibodies
BRPI0906877A2 (pt)	2015-07-28	Anticorpos anti-trkb aperfeiçoados
DK3118220T3 (da)	2019-09-23	Protein
EP2254911A4 (en)	2011-10-19	HUMANIZED ANTI-C5aR ANTIBODIES
HUE056626T2 (hu)	2022-02-28	Antitestkészítmény
BRPI0814252A2 (pt)	2015-04-14	Formulações de anticorpo
PT2889310T (pt)	2018-03-26	Formulações de anticorpo
SI2126093T1 (sl)	2013-01-31	IzboljĹˇanje priprave proteinov
DK2059533T3 (da)	2013-02-25	Multispecifikke antistoffer
EP2215246A4 (en)	2011-08-10	PROTEIN SCAFFOLDS
DK2046826T3 (da)	2011-10-24	Exendin-fusionsproteiner
HRP20171011T1 (hr)	2017-09-22	ANTI-eMET ANTITIJELO
BRPI0907237A2 (pt)	2015-07-14	Anticorpo anti-cldn6
EP2211903A4 (en)	2011-07-06	CLL-1 ANTIBODY
FI20075278A0 (fi)	2007-04-20	Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
BRPI0820819A2 (pt)	2015-06-16	Formulação de anticorpos